Company Description
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel.
The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis.
It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction.
In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases.
The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001.
The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
| Country | Israel |
| Founded | 1994 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Motti Farbstein |
Contact Details
Address: 26 Ben Gurion Street Ramat Gan, L3 5257346 Israel | |
| Phone | 972 39241114 |
| Website | canfite.com |
Stock Details
| Ticker Symbol | CANF |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | ILS |
| CIK Code | 0001536196 |
| CUSIP Number | 13471N201 |
| ISIN Number | US13471N3008 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Pnina Fishman Ph.D. | Founder, Chief Scientific Officer and Executive Chairperson |
| Motti Farbstein | Chief Executive Officer and Chief Financial and Operating Officer |
| Dr. Sari Fishman Ph.D. | Vice President of Business Development |
| Dr. Ilan Cohn Ph.D. | Co-Founder and Director |
| Dr. Stephen A. Harrison FACP, M.D. | Member of Clinical Advisory Board and Consulting Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 29, 2024 | 6-K | Report of foreign issuer |
| May 22, 2024 | 6-K | Report of foreign issuer |
| May 13, 2024 | 6-K | Report of foreign issuer |
| May 9, 2024 | 6-K | Report of foreign issuer |
| May 6, 2024 | 6-K | Report of foreign issuer |
| Apr 25, 2024 | 6-K | Report of foreign issuer |
| Apr 15, 2024 | 6-K | Report of foreign issuer |
| Apr 9, 2024 | EFFECT | Notice of Effectiveness |
| Apr 5, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 5, 2024 | POS AM | Post-Effective amendments for registration statement |